 Ironwood Pharmaceuticals Inc. NASDAQ:IRWD has the dubious distinction of owning one of the 10 biggest drug trial flops of 2020, according to FierceBiotech. The Boston-based companys once-promising treatment for gastroesophageal reflux disease was relegated to the trash bin in September when it failed a phase 3 study. 